<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003453</url>
  </required_header>
  <id_info>
    <org_study_id>PEA-XMA-20</org_study_id>
    <nct_id>NCT05003453</nct_id>
  </id_info>
  <brief_title>The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema</brief_title>
  <official_title>The Effectiveness of a Topical Palmitoylethanolamide Formulation (Levagen+) for Reducing the Symptoms of Eczema Versus a Comparator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RDC Clinical Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RDC Clinical Pty Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind, randomised, non-clinical study with 2 groups (1 investigational group&#xD;
      and 1 comparator group) aiming to assess the effectiveness of PEA for reducing eczema&#xD;
      severity compared to a base comparator moisturiser in healthy adults aged over 18 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eczema area and severity index (SA-EASI)</measure>
    <time_frame>Baseline prior to commencement, Week 2 and Week 4</time_frame>
    <description>Change in eczema area and severity index (SA-EASI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in itchiness (pruritus numerical rating scale)</measure>
    <time_frame>Baseline prior to commencement, Week 2 and Week 4</time_frame>
    <description>Change in self-reported itchiness (pruritus numerical rating scale). Minimum value = 0, no pruritus. Maximum value = 10, Very severe pruritus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in topical anti-inflammatory use</measure>
    <time_frame>Baseline prior to commencement, Week 2 and Week 4</time_frame>
    <description>Change in self-reported topical anti-inflammatory use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient eczema self assessment (Patient Orientated Eczema Measure)</measure>
    <time_frame>Baseline prior to commencement, Week 2 and Week 4</time_frame>
    <description>Improvement in POEM. Minimum value 0 - clear or almost clear, Maximum value 28 - Very severe eczema</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Eczema, Atopic</condition>
  <arm_group>
    <arm_group_label>1.5% Palmitoylethanolamide (PEA) sold as Levagen+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational product will be provided as a topical cream containing 1.5% PEA and participants will be asked to apply to their affected site 2-3 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A comparator placebo moisturiser cream (an unscented moisturizing base cream) will be provided and applied in the same manner as the active ingredient group. Participants will be asked to apply to their affected site 2-3 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.5% Palmitoylethanolamide (PEA) sold as Levagen+</intervention_name>
    <description>A topical cream containing 1.5% PEA applied to the affected site 2-3 times daily, liberally to coat and cover affected area.</description>
    <arm_group_label>1.5% Palmitoylethanolamide (PEA) sold as Levagen+</arm_group_label>
    <other_name>PEA, Levagen+</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2-3 times daily, liberally to coat and cover affected area.</description>
    <arm_group_label>Placebo comparator</arm_group_label>
    <other_name>Moisturising cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (over 18)&#xD;
&#xD;
          -  Suffering from atopic eczema with symptoms of redness, dry skin, scaling and/or&#xD;
             itchiness on hands or arms&#xD;
&#xD;
          -  Otherwise healthy&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active allergic skin responses&#xD;
&#xD;
          -  Unstable or serious illness (eg kidney, liver, GIT, heart conditions, diabetes, mood&#xD;
             disorders, cancer)&#xD;
&#xD;
          -  Use of immunosuppressive medication within the last 3 months&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Chronic past and/or current alcohol use (&gt;14 alcoholic drinks week)&#xD;
&#xD;
          -  Allergic to any of the ingredients in active or comparator formula&#xD;
&#xD;
               -  An unstable illness is any illness that is currently not being treated with a&#xD;
                  stable dose of medication or is fluctuating in severity. A serious illness is a&#xD;
                  condition that carries a risk of mortality, negatively impacts quality of life&#xD;
                  and daily function and/or is burdensome in symptoms and/or treatments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Briskey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Queensland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Rao, PhD</last_name>
    <phone>+61 414 488 559</phone>
    <email>amanda@rdcglobal.com.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Briskey, PhD</last_name>
    <phone>+61 421 784 077</phone>
    <email>d.briskey@uq.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RDC Global Pty Ltd</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Amanda Rao, PhD</last_name>
      <phone>+61 414 488 559</phone>
      <email>amanda@rdcglobal.com.au</email>
    </contact>
    <contact_backup>
      <last_name>David Briskey, PhD</last_name>
      <phone>+61 421 784 077</phone>
      <email>d.briskey@uq.edu.au</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palmidrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

